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Abstract
Background: Transarterial chemoembolization (TACE) is recommended as a treatment for unresectable
hepatocellular carcinoma (HCC) in patients with normal underlying liver function. The efficacy of TACE in
cirrhotic patients with compromised liver function is unknown.
Methods: All ‘first’ TACE interventions for HCC performed at a single institution from 2008 to 2012 were
retrospectively reviewed (n = 190). Liver function was quantified via the Child's score. Tumour necrosis
after TACE was quantified via the mRECIST criteria.
Results: The ‘first’ TACE procedures of 100 Child's A and 90 Child's B/C cirrhotic patients were
evaluated. As expected, the lab-model for end-stage liver disease (MELD) score was significantly higher
in the Child's B/C group. Although the number of tumours were similar between the groups, both the size
of the largest tumour and the total tumour diameter were greater in the Child's A group. There were no
significant differences in post-TACE tumour necrosis between groups. The median survival after TACE
was significantly longer in the Child's A compared with Child's B/C patients (21.9 versus 13.7 months,
P = 0.03).
Conclusions: TACE appears to be equally efficacious in cirrhotic patients regardless of their Child's
classification based upon equivalent mRECIST measures of tumour necrosis. However, inferior survival
after TACE was observed in the Child's B/C group.
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Introduction
Transarterial chemoembolization (TACE) is the standard of care
for intermediate stage hepatocellular carcinoma (HCC) in patients
that are not candidates for surgical resection or tumour ablation.1,2
Population-based data demonstrates that TACE is the most
common oncological treatment performed forHCC amongMedi-
care patients in the United States.3 Review of the Scientific Registry
of Transplant Recipients (SRTR) data on liver transplantation for
HCC also demonstrates that TACE is the most common bridging
therapy offered to >70% of patients on a waiting list in the US.4
Current practice guidelines from the American Association for
the Study of Liver Disease (AASLD) recommend TACE ‘as “first”
line non-curative therapy for non-surgical patients with large/
multifocal HCCwho do not have vascular invasion or extrahepatic
spread. . . .’5,6 The AASLD’s recommendation, however, only apply
to Child–Pugh class A patients.5,6 The AASLD further states that
‘patients with advanced liver disease (Child–Pugh class B or C)
and/or clinical symptoms of end-stage cancer should not be con-
sidered for these treatments as they have an increased risk of liver
failure and death.’5,6
The AASLD practice guidelines for TACE were based upon
a heterogeneous collection of clinical studies, many of which
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utilized non-selective lobar chemoembolization approaches.7,8
Often, there is significant ‘innocent bystander’ hepatocyte necrosis
as a complication of non-selective lobar chemoembolization
approaches.9,10 There is increasing recognition that selective
HCC chemoembolization approaches, where only the hepatic
arterial branches directly supplying the HCC are treated, may
be performed with minimal (non-targeted) collateral damage
to adjacent uninvolved hepatic parenchyma.10 The development
of microcatheters and the application of super-selective emboli-
zation techniques have prompted the University of Alabama
at Birmingham (UAB) Liver Tumor Board to increasingly
offer TACE to select cirrhotic patients with compromised liver
function.
The purpose of this study was to measure the safety and efficacy
of TACE procedures performed as first-line therapy in cirrhotic
patients with Child–Pugh class B or C compromised liver func-
tion. The outcomes in the Child–Pugh B or C patients were com-
pared with a contemporaneous group of Child–Pugh A cirrhotic
patients treated similarly. Our hypotheses were (i) TACE can be
performed safely in Child–Pugh B or C cirrhotic patients, (ii)
there will be no difference in HCC tumour necrosis in Child–
Pugh A compared with Child-Pugh B or C patients and (iii) there
will be equivalent post-TACE survival in Child–Pugh A compared
with Child–Pugh B or C patients.
Methods
Ethics approval for this study was obtained from the University of
Alabama Institutional Review Board (Protocol #X100310006). A
retrospective chart review was performed for all patients receiving
a TACE at UAB between January 2008 and June 2012. Patients




either by biopsy or by the presentation of classic HCC radiological
features of a >2-cm hypervascular lesion arising in the setting of
cirrhosis with arterial phase enhancement and portal venous phase
washout.11 The decision to offer TACE to patients with HCC was
made by amulti-disciplinary liver tumour board at UAB including
medical oncologists, surgeons, hepatologists and interventional
radiologists. Candidacy for TACE in Child–Pugh A patients was
determined by established AASLD practice guidelines.5,6 Select
Child–Pugh class B and C cirrhotic patients were offered TACE if
they had an ECOG functional status of 0 or 1, limited tumour
burden andmedically controlled symptoms of hepatic decompen-
sation. There was no absolute cut-off model for end-stage liver
disease (MELD) score, Child–Pugh score, bilirubin, international
normalized ratio, etc. However, most Child–Pugh class B and C
patients offeredTACEhad ahyperbilirubinemia thatwas predomi-
nantly indirect and/or hypoalbuminemia out of proportion to the
overall clinical assessment. Patients could have ascites although the
ascites needed to be controlled with diuretics; an active need for
paracentesis was a contraindication. Patients could also have a
history of encephalopathy but this needed to be controlled medi-
cally without evidence of recent hospitalizations.Child–Pugh class
B or C patients were not offered TACE if they had medically
refractory ascites or poorly controlled encephalopathy.
A list of all patients treated with TACE between January 2008
and June 2012 was generated from the UAB Interventional Radi-
ology procedures electronic database (n = 348). Patients were
excluded if they had a non-HCC tumour type (n = 45) and if the
TACE procedure performed was not the ‘first’ TACE intervention
(n = 113) (Fig. 1). HCC tumours that had previously been treated
operatively or with another locoregional therapy such as
radiofrequency ablation or external beam radiotherapy were
excluded from the study. Patients taking chemotherapeutic agents
before and/or after the procedure were included in the study. All
patients were felt to have cirrhosis based upon a combination of
platelet counts and radiographical criteria.
Imaging
Patients were only included if they had high-quality three phase or
four phase computed tomography imaging or liver protocol mag-
netic resonance imaging (MRI) within 75 days prior to and after
the TACE procedure.
HCC tumour assessment and post-TACE
tumour necrosis quantification
After an extensive training period, two second year medical stu-
dents (D.D. and M.B.) independently reviewed CT and MRI
studies performed before and after TACE for all patients. The
body radiology fellow (J.Z.) taught the medical students about the
basics of multiphasic CT and outlined a consistent approach to
calculating axial tumour dimensions and identifying post-TACE
tumour necrosis. After these teaching sessions, the fellow and
medical students jointly worked through 20 patients together. The
medical students, body fellow and senior staff then reviewed 20
patients independently and the results were reviewed to verify
consistency. The medical students then reviewed all CT imaging
independently. The medical students saved the marked images
indicating caliper and contrast enhancement measurements. The
UAB body radiology fellow independently reviewed all CT and
MRI studies and confirmed all measurements. A staff radiologist
(K.S.) with 19 years of experience in body imaging confirmed all
quantitative data. When evaluating the cross-sectional imaging,
the assessors were blinded to the Child–Pugh class and MELD
score.
The tumour response was assessed via the modified response
evaluation criteria in solid tumours (mRECIST). Using CT or
MRI studies obtained prior to the procedure, a pre-TACE tumour
size was determined. The measurements were then repeated on
CT or MRI studies obtained after the procedure. Consistent with
mRECIST criteria, only axial images were used for tumour size
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measurements. Electronic calipers were used to measure the
longest diameter of each tumour and the widest perpendicular
measurement in the same image for use in calculating cross-
sectional tumour diameter.
In 2008, the AASLD modified the National Cancer Institute
RECIST criteria to unify assessment of a radiographical response
for HHC.12 The modified RECIST criteria response is based on
residual arterial enhancement rather than purely tumour shrink-
age measured by the greatest diameter of the lesion. Response data
are presented for the largest lesion only, herein referred to as the
index lesion. There are four categories of tumour response accord-
ing to mRECIST: complete response, partial response, stable
disease or progressive disease.12 A complete response is defined as
the disappearance of tumour arterial enhancement. A partial
response is defined as at least a 30% decrease in the diameter of
arterial enhancement. Stable disease is defined as a response that
did not fall into the partial response or progressive disease cat-
egory. Progressive disease is defined as growth of at least 20% of
the sum of the longest diameter of the lesions.
TACE protocol
Thedecision toofferTACEas loco-regional oncological therapy for
patients with HCC was made at the UAB multidisciplinary liver
tumour board. There were two general approaches to TACE: single
or oligo-HCC tumours were generally treated with a Lipodiol-
based targeted TACE whereas multifocal HCC tumours were
treated with drug eluting beads (DEBS). Lipodiol-based TACE
consisted of HCC embolization with a mixture of Lipodiol, 50 mg
of Doxorubicin and 400-μmEmbozene®microspheres (Celonova,
San Antonio, TX, USA). DEBS TACE consisted of either LC beads
(Biocompatibles UK Ltd, Farnham, UK) or QuadraSpheres®
expanding microspheres (BioSphere Medical, Roissy en France,
France). These beads were eluted with 50 mg Doxorubicin.
Statistical analysis
Patient demographics, clinical history, laboratory data and cross-
sectional imaging characteristics were collected. Pre-TACE
imaging CT andMRI variables included tumour location (periph-
eral versus central, right lobe versus not), number of lesions, size of
tumours and total diameter of three of the largest tumours in the
case of multifocal HCC. Data collected from post-TACE CT and
MRI imaging includedHCC tumour necrosis asmeasured accord-
ing tomRECISTcriteria.12 To allowcommon statistical procedures,
the analysis was restricted to examination of the index HCC
tumour that was defined as the largest tumour (if more than one
tumour per patient had been used in the analysis, the common
assumption of independent data observations would have been
violated).A two sample t-test was used to comparemeans between
the groups. The primary analytic approach for dichotomous vari-
ables utilized chi-square analyses. Kaplan–Meier curves were con-
structed to evaluate patient survival. Survival probabilities were
analysedwith the log-rank test. For all inferences, the probability of
a Type I error (α) was set to 0.05.All analyses were conducted using
SAS 9.2 (SAS Inc., Cary, NC, USA).
Results
Patient demographics
There were 100 TACE patients in the Child–Pugh class A group
and 90 TACE patients in the Child–Pugh class B or C group who
Excluded 45 TACE procedures
performed on non-HCC tumours
348 TACE procedures
performed at UAB between 
Jan 2008 and June 2012
303 TACE procedures
performed for HCC tumours
190 HCC patients
received 1st TACE procedure
Excluded 113 TACE procedures









Figure 1 Flow diagram of 348 TACE procedures demonstrating the inclusion and exclusion criteria used to select patients for this
retrospective study. TACE, Transarterial chemoembolization; HCC, hepatocellular carcinoma
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underwent TACE as an initial locoregional therapy. The Child–
Pugh class A group was older than the Child–Pugh B or C group
(63.4 ± 10.5 compared with 59.6 ± 6.9, P = 0.0038). There were no
differences in gender or race between the groups. There were more
Child–Pugh class A patients with hepatitis B (9.0% versus 2.2%,
P < 0.05), fewer patients with hepatitis C (48.0% versus 62.2%,
P < 0.05) and a trend towards fewer patients with alcoholic liver
disease (21.0% versus 32.2%, P < 0.1) compared with the Child–
Pugh B or C patients. A platelet count over 100 × 109/l was
observed in 69.0% of the Child–Pugh class A patients whereas a
platelet count less than 100 × 109/l was observed in 74.4% of the
Child–Pugh class B/C patients (P < 0.0001). As expected, the
lab-MELD score was significantly lower in the Child–Pugh class A
patients compared with the Child–Pugh class B or C patients (8.7
± 1.9 versus 13.4 ± 3.8, P < 0.0001). (Table 1)
Tumour characteristics
Significant demographic differences in tumour characteristics
were observed between the Child–Pugh class A and B/C groups.
Although the alpha-fetoprotein levels and tumour number were
not different, the Child–Pugh class A patients had a larger tumour
diameter (5.5 ± 3.2 versus 3.8 ± 2.0, P < 0.001) and larger summed
diameters of the three largest tumours (7.5 ± 5.2 versus 5.2 ± 2.5,
P = 0.003). In addition, more of the Child–Pugh class A patients
were on Sorafenib within 90 days before or after TACE compared
with Child–Pugh class B/C patients (39.0% versus 25.6%, P <
0.05) (Table 1).
TACE procedures
There were no significant differences in the number of TACE
procedures performed in each group. A single TACE procedure
was performed in 56.0% of the Child–Pugh class A patients and in
57.5% of the Child–Pugh class B/C patients. Two TACE pro-
cedures were performed in 33% of each group and approximately
10% of each group had three or more TACE procedures. Further-
more, there was no significant difference in the number of repeat
TACE procedures performed within 6 months of the ‘first’ TACE
procedure (24.0% A versus 20.7% B/C, P = 0.59). There also were
no significant differences in the use of Lipiodol or DEBS between
the groups. Although non-selective (lobar) TACE was uncommon
(15/190, 8%), more non-selective TACE procedures were per-
formed in the Child–Pugh class A patients compared with the
Child–Pugh B/C patients (12.2% versus 3.3%, P = 0.02) (Table 1).
HCC tumour necrosis
There were no significant differences in TACE-induced HCC
tumour necrosis between groups as quantified by mRECIST cri-
teria. There was a higher proportion of the Child–Pugh class B/C
group that demonstrated a complete radiographical response after
TACE; however, the difference was not statistically significant
(Fig. 2). On subgroup analysis, there also were no significant dif-
ferences in TACE-induced HCC tumour necrosis when compar-
ing selective and non-selective TACE approaches (P = 0.88)
Changes in hepatic function post-TACE
Measures of liver function were recorded immediately prior to
TACE and 1 month post-TACE. The difference in liver function
measurements (pre- to post-TACE) was compared between the
Child–Pugh class A and B/C groups. (Table 2) There was a slight,
but statistically significant, increase in the Child–Pugh andMELD
scores in the Child–Pugh A group compared with the Child-Pugh
B/C group (Child-Pugh score: Δ+0.35 points versus Δ 0.0 points,
P < 0.001; MELD score: Δ+0.71 points vs. Δ-0.01 points, P <
0.001). Similarly, there was a slight, but statistically significant
decrease in the serum albumin in the Child–Pugh A group com-
pared with the Child–Pugh B/C group (Δ-0.21 versus Δ-0.05 g/dl,
P < 0.001). In contrast, there were no significant differences in
total bilirubin, INR, creatinine, ascites or encephalopathy meas-
urements between the Child–Pugh groups.
Subgroup analyses were performed comparing changes in liver
function measurements as a function of TACE vehicle. No differ-
ence in liver function measurements was observed between
patients treated with Lipiodol or DEBS. (Table 3) Subgroup analy-
ses were also performed comparing changes in liver function
measurements as a function of the TACE approach. No difference
in liver function measurements was observed between selective
and non-selective TACE approaches.
Survival
There was no 30-day mortality observed in either the Child–Pugh
class A or the Child–Pugh class B/C groups. There were 90-day
mortalities observed in two Child–Pugh class A and four Child–
Pugh class B/C patients (P = 0.90). Kaplan–Meier curves were
constructed for each group (Fig. 3). The survival curves separate
at 3 months and reach maximal separation by 12 months.
Superior survival was observed in the Child–Pugh class A group
compared with the Child–Pugh class B/C group (log rank test,
P = 0.03). The median survival estimate from the Kaplan–Meier
curves was 21.9 months in the Child–Pugh class A compared with
13.7 months in the Child–Pugh class B/C group.
A Cox proportional hazards model was constructed to identify
pre-TACE variables associated with post-TACE mortality in the
Child–Pugh class B/C group. Only total tumour diameter (hazard
ratio 1.26, 95% confidence interval 1.10–1.44, P < 0.001) was
independently associated with post-TACE mortality in Child–
Pugh class B/C patients.
Discussion
The most important finding demonstrated in this study is that
TACE can be performed safely in select patients with compromised
liver function. No peri-procedural or 30-day mortalities were
observed in either group, in contrast to the 10–20%mortality risk
reported in an older study of non-Child–Pugh class A patients13
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that is frequently quoted in TACE reviews.14 Changes in liver
function were minimally worse in both groups after TACE. The
difference in liver functionmeasurements (pre- to post-TACE)was
comparable between the Child–Pugh class A and B/C groups.
Other previous studies have also documented no significant long-
term worsening of liver function after TACE in cirrhotics.15
The group of Child–Pugh B/C patients, however, is undoubt-
edly a selected subgroup of patients with compromised liver func-
tion in spite of an average lab MELD score that was five points
higher than the Child–Pugh class A patients. Piscaglia et al. 16
demonstrates the inverse association between rising Child–Pugh
scores and candidacy for TACE. While TACE may be a safe
Table 1 Baseline demographics and tumour characteristics for the Child–Pugh class A and Child–Pugh class B/C groups
Variable Child–Pugh class A Child–Pugh class B/C Significance
Group n = 100 n = 90
Age (years) 63.4 ± 10.5 59.6 ± 6.9 0.01





Aetiology of liver diseasea
Alcohol 21.0% 32.2% 0.08
HBV 9.0% 2.2% 0.04
HCV 48.0% 62.2% 0.04
NASH 21.0% 22.2% 0.84
Haemochromatosis 5.0% 1.1% 0.22
Portal Hypertension <0.0001
Platelet count < 100b 31.0% 74.4%
Platelet count >100b 69.0% 25.5%
Pre-TACE lab values
Lab-MELD score 8.7 ± 1.9 13.4 ± 3.8 <0.0001
Alpha-fetoprotein 1873.4 ± 8094.2 1624.2 ± 8288.8 0.85
Tumour characteristics
Number of tumours 1.5 ± 0.7 1.5 ± 0.7 0.95
Size of largest tumourc 5.5 ± 3.2 3.8 ± 2.0 <0.001
Total tumour diameterd 7.5 ± 5.2 5.2 ± 2.5 0.003
Sorafenibe 39.0% 25.6% 0.04
Type of TACE
Lipiodol 49.0% 58.9% 0.17




Repeat TACE within 6 months 24.0% 20.7% 0.59
Total TACE procedures
1 56.0% 57.5% 0.92
2 33.0% 33.3%
3 or more 11.0% 9.2%
aSome patients had more than 1 aetiology of liver disease.
bPlatelet units of measurement is × 109/l.
cAxial diameter of largest tumour measured in centimetres.
dSum of axial diameters of the three largest lesions measured in centimetres.
eSorafenib use defined as within 90 day pre- or post-TACE.
HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis; MELD, model for end-stage liver disease (range 6–40); TACE,
transarterial chemoembolization.
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oncological intervention in select patients with Child–Pugh class
B/C cirrhosis, previous studies have demonstrated that Child–
Pugh classification is significantly associated with post-TACE
complications,17 and the development of radiocontrast-induced
nephropathy post-TACE.18 Many studies have also confirmed that
Child–Pugh class is significantly associated with survival post-
TACE.19–23 Other studies have reported on the individual compo-
nents of the Child–Pugh scoring system. Dr Yao’s group measured
risk factors associated with irreversible hepatotoxicity in a large
series of TACE patients treated at the University of California,
San Francisco, and reported bilirubin>4 mg/dl, elevated INR,
albumin<2 g/l, creatinine>2 mg/dl, large ascites, encephalopathy
and a MELD score > 19 were independently associated with
mortality.24
Another important observation from this study is that equiva-
lent tumour necrosis can be achieved in Child-Pugh class B/C
patients. Worsening liver disease per se does not appear to affect
the process of administering chemoembolization materials and
inducing tumour necrosis. This study demonstrated a practice
pattern of preferentially performing selective TACE in Child–
Pugh class B/C patients. Repeat TACE was performed in 42.5%
of the Child–Pugh class B/C patients. It is important to note,
however, the tumour selection bias present in the Child–Pugh
class B/C patients. The oncological indications for TACE were
more conservative than those for Child–Pugh class A patients as
evidenced by smaller HCC tumours and a reduced total tumour
diameter in Child-Pugh class B/C patients. In contrast, the indi-
cations for TACE in Child–Pugh class A were much more liberal
given the preserved liver function.
Perhaps the biggest question raised by this study is whether or
not the median survival of 13 months observed in the Child–Pugh
B/C patients represents improved survival in response to life pro-
longing therapy compared with best medical care? Unfortunately
this study was not able to answer this question because we have no
untreated group for comparison. It is also hard to identify studies
in the literature to use as a reasonable survival comparison owing
to the heterogeneity of patients in the different studies. Approxi-
mately 70–100% of patients enrolled in HCC TACE studies only
include Child–Pugh class A patients14 and meta-analyses have
been unable to quantify the effect of Child–Pugh class and sur-
vival owing to outcomes data not being stratified by Child–Pugh
class.8 In addition, most chemotherapy trials only include patients
that have failed or are not candidates for locoregional therapy.25,26
It is tempting to use the index Sorafenib study25 as a frame of
reference, which demonstrated a median survival of 10.7 months
in the treated Child-Pugh class A patients (although these patients
either had failed or were not candidates for locoregional thera-
pies). The follow-up GIDEON trial (observational Sorafenib)
demonstrates a median survival of 3.6 months in Child–Pugh
class B and 2.1 months in Child–Pugh class C patients.26 The
historical survival in the control group (best supportive care) of
one of the randomized clinical trials that served to demonstrate
the survival benefit of TACE was 6 months.27 A more recent study
of Child–Pugh B patients demonstrated a median survival of 8
months, although survival differed greatly in Child–Pugh class B7,
B8 and B9 patients.16 Given these clinical outcomes as a relative
comparison, it seems that a median survival of 13 months in a
group of Western patients with both advanced liver disease and
advanced HCC probably represents a survival benefit.
Our clinical observation is that there is considerable disparity in
the chemoembolization techniques and outcomes from centre to
centre. Review of the literature confirms these observations based
upon the large variability in outcomes reported for TACE trials.14
The use of selective or non-selective (lobar) approaches is operator
dependent and varies with the skill set of the interventionist. There
is also a growing trend away from traditional Lipiodol to DEBS as
the platform for delivering locoregional chemoembolization
material.28 Selective and sub-selective approaches were used for
many of the Child–Pugh class B/C patients in this study, especially
for patients with compromised liver function. There are always
some ‘innocent bystander’ (non-cancerous hepatocyte) deaths
with TACE.9,10 Our approach is to use a ‘smart-bomb’ (selective)
approach,as opposed to a‘nuclear-bomb’(non-selective) approach
to minimize non-cancerous hepatocyte death in an effort to pre-
serve existing liver function. We would caution against non-
selective TACE especially in Child–Pugh class B/C patients with
HCC although, admittedly, our concerns are theoretical and not
based upon the results of our study or a personal experience of
higher complication rates aswe generally try to avoid this approach
(as evidenced by a 3.3% frequency of non-selective TACE inChild–
Pugh B/C patients). Notably, the 10–20% mortality after TACE in
Child–Pugh class B/C patients reported by Vetter et al. in 1991
involved non-selective approaches.13
As with all retrospective studies, this report has several limita-
tions. First is the selection bias observed in the Child–Pugh



































Figure 2 Distribution of HCC tumour necrosis* after TACE as meas-
ured by mRECIST criteria. * Only data for index lesion are presented
and considered for statistical analysis. HCC, hepatocellular carci-
noma; TACE, transarterial chemoembolization; mRECIST, modified
response evaluation criteria in solid tumours
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perspectives. Therefore, our findings are not applicable to all
patients with significant liver dysfunction. Second, we commonly
performed selective TACE procedures whereas it is our impres-
sion that many TACE procedures performed nationwide are
actually non-selective lobar approaches, which may limit the
generalizability of the study. Finally, we do not have a control
group of Child–Pugh class B/C that was not treated with TACE for
comparison. Our liver tumour clinic evaluates many HCC
patients with compromised liver dysfunction for which no treat-
ment is recommended. However, we chose to not compare to this
palliative group owing to the selection bias between those patients
that were recommended therapy and those not recommended
therapy.
In conclusion, this study of 90 patients undergoing TACE pro-
cedures as the first-line locoregional therapy in select Child–Pugh
class B/C patients demonstrates that this intervention can be per-
formed relatively safely with equivalent tumour necrosis results
when compared with Child-Pugh class A patients. Post-TACE
survival outcomes were inferior compared with the Child–Pugh
class A patients, but TACE intervention in this select group
Table 2 Comparison of baseline and post-TACE measures of hepatic function
Child–Pugh class Aa Child–Pugh class B/Ca Significanceb
Pre-TACE Post-TACE Pre-TACE Post-TACE
Child–Pugh score 5.62 ± 0.51 5.97 ± 0.83 8.01 ± 1.14 8.01 ± 1.11 <0.001
MELD score 8.70 ± 1.88 9.41 ± 2.41 13.38 ± 3.82 13.37 ± 4.88 <0.001
Total bilirubin 1.06 ± 0.38 1.19 ± 1.13 1.97 ± 0.84 2.03 ± 0.86 0.83
INR 1.11 ± 0.16 1.15 ± 0.18 1.34 ± 0.24 1.41 ± 0.76 0.58
Creatinine 0.92 ± 0.24 0.99 ± 0.31 1.13 ± 0.24 1.20 ± 1.02 0.07
Albumin 3.49 ± 0.38 3.28 ± 0.47 2.86 ± 0.47 2.81 ± 0.51 <0.001
Ascitesc 1.00 ± 0.00 1.04 ± 0.20 1.44 ± 0.56 1.43 ± 0.57 0.60
Encephalopathyc 1.02 ± 0.14 1.06 ± 0.24 1.53 ± 0.50 1.53 ± 0.50 0.22
aChild–Pugh class assignment based upon pre-TACE measurements.
bStatistical analyses are made between the change (delta) between the pre- and post-TACE values and compared between the Child–Pugh class A
vs. B/C HCC patients.
cReported as 1, 2 or 3 per the Child–Pugh scoring system.
TACE: TACE, transarterial chemoembolization; MELD, model for end-stage liver disease (range 6–40); INR, international normalized ratio; DEBS, drug
eluting beads.
Table 3 Comparison of baseline and post-TACE measures of hepatic function stratified by TACE vehicle
Lipiodol DEBS Significanceb
Pre-TACE Post-TACE Pre-TACE Post-TACE
Child–Pugh Aa
MELD 8.80 ± 1.95 9.26 ± 2.19 8.60 ± 1.83 9.54 ± 2.61 0.34
Child–Pugh 5.64 ± 0.53 5.86 ± 0.80 5.60 ± 0.49 6.02 ± 0.86 0.18
Child–Pugh B/Ca
MELD 12.66 ± 3.78 13.00 ± 5.26 13.84 ± 3.82 13.62 ± 4.46 0.58
Child–Pugh 8.09 ± 1.20 7.88 ± 1.07 7.96 ± 1.10 8.10 ± 1.15 0.37
aChild–Pugh class assignment based upon pre-TACE measurements.
bStatistical analyses are made between the change (delta) between the pre- and post-TACE values and compared between Lipiodol and DEBS.




































Figure 3 Kaplan–Meier curve demonstrating increased overall sur-
vival (from the date of ‘first’ TACE procedure) in Child–Pugh class A
patients compared with Child–Pugh class B/C patients (log rank
test, P = 0.03)
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